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Summary Sequential methotrexate (Mtx) absorption studies were undertaken in 127 children undergoing
treatment for childhood non-T acute lymphoblastic leukaemia (ALL) to determine whether serum drug
concentration, clearance and dosage affect event free survival (EFS). Higher serum concentration and area
under the plasma concentration curve (AUC) were not associated with an improved EFS. Methotrexate
clearance was not found to be of prognostic significance.
Patients who tolerated only low 6-mercaptopurine (6-MP) doses because of neutropaenia and those who
randomly were prescribed higher doses of Mtx had a lower rate of leukaemia relapse after the completion of
therapy. This suggests that the use of maintenance therapy in maximally tolerated doses may be associated
with an increased survival in childhood ALL.
Although methotrexate (Mtx) has been used in the treatment
of childhood ALL for over 40 years and is one of the major
drugs utilised in the continuing or maintenance therapy of
this disease, the optimum method of administration is still
unknown. Wide variations in absorption occur following oral
administration with resultant upredictable serum concentra-
tions (Freeman Narrod, 1962; Kearney et al., 1979; Craft et
al., 1980; Pinkerton et al., 1980; Balis et al., 1983) and it has
been suggested that the lower and more variable serum con-
centrations after oral Mtx may account for some relapses in
children with ALL. Therefore it may be that intramuscular
(IM) Mtx could reduce variability and improve prognosis.
To explore this possibility a study was commenced in 1979
at the Hospital for Sick Children, Great Ormond Street in
which patients were randomised to receive oral or IM Mtx
during maintenance therapy (Chessells et al., 1987).
Drug doses have previously been related to event free
survival (EFS) in childhood ALL and other malignancies
with patients receiving half doses having a higher incidence
of disease recurrence than those on full dosage (Pinkel et al.,
1971; Gaynon et al., 1987). From this it has been extra-
polated that higher serum concentrations of cytotoxic drugs
are associated with a greater chance of prolonged disease
remission. In patients with ALL given oral Mtx, higher I h
serum concentrations have been related to an improved EFS
(Craft et al., 1980). Variability in serum concentration fol-
lowing intravenous high dose Mtx has been shown to be
associated with disease free survival, a more rapid clearance
and a lower steady state concentration inferring a poor prog-
nosis (Evans et al., 1984; Evans et al., 1986). In order to
relate serum Mtx concentration to relapse free survival in
childhood ALL sequential Mtx absorption studies have been
carried out on 127 children with ALL. The overall outcome,
differences in Mtx pharmacokinetics between IM and oral
administration and inter- and intraindividual variability in
absorption have already been reported (Chessells et al., 1987;
Pearson et al., 1987). This paper relates the pharmacokinetics
and dosage of Mtx and the 6-mercaptopurine (6-MP) dosage
to EFS in childhood ALL.
Patients and methods
Between 1979 and 1982 all children with non-T ALL receiv-
ing therapy at the Hospital for Sick Children, Great Ormond
Street, London, were treated according to the PLOD proto-
col (Chessells et al., 1987). Induction of remission was
achieved with the use of intravenous vincristine and dauno-
rubicin, oral prednisolone and subcutaneous asparaginase.
Central nervous system therapy comprised six intrathecal
injections of Mtx and cranial irradiation either with 24 Gy,
for those treated before 1981 or 18 Gy after 1981. Continuing
(maintenance) therapy was with pulses of constant dose vin-
cristine (1.5 mg m-2) and prednisone (40 mg m-2) for 5 days)
every 6 weeks, daily 6-MP for 2 weeks out of three at a
variable maximally tolerated dose of between 70 and 100 mg
m-2 adjusted to maintain the absolute neutrophil count
(ANC) above 1.0 x 1091, and Mtx at a constant dose of
20 mg m2 given once per week early in the morning in a
fasting state. Patients were randomised to receive either oral
or IM Mtx. Prophylactic cotrimoxazole was not given during
therapy. The children's platelet count and ANC were
measured at least every 3 weeks. Continuing therapy was
given for 96 weeks.
One hundred and sixty-four patients were entered onto this
protocol, 150 entered remission and of these 144 were ran-
domised to receive either oral or IM Mtx. All patients have
been followed for a minimum of 7 years to 1st January 1990,
i.e. for at least 5 years off therapy.
The parents of 17 children who were randomised to receive
oral or IM Mtx did not give permission for their children to
enter the pharmacokinetic studies. Mtx absorption studies
were carried out on the remaining 127 patients (64 who
received oral and 63 IM Mtx). Their ages ranged from 0.86
to 13.62 years (median 4.34) and presenting white cell count
ranged from 0.4-769 x 1091' (median 8.7 x 1091-'). All
studies were carried out under standardised conditions early
in the morning, in the fasting state, at the commencement of
continuing therapy (3 months after diagnosis) and again at
12 and 18 months. Blood samples were obtained at 0, half, 1,
2, 3, 5, 8, 12 and 24 h and Mtx was measured by modified
EMIT assay with a lower limit of detection of 0.01 liM
(Gushaw & Miller, 1978; Mills, S. unpublished results).
For each absorption study the median concentration was
noted and the area under the serum concentration curve for
the first 24 h (AUC24) was determined using the linear trape-
zoid method. For seven patients calculations of the AUC was
not possible as not all data points were available. For those
receiving IM Mtx the clearance was calculated (dose divided
by AUC24) assuming 100% bioavailability.
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Children had the percentage of the recommended protocol
dose of 6-MP and Mtx (in mg m-2) that they were actually
prescribed calculated. This and the mean ANC was deter-
mined for each of the eight 12 week periods during continu-
ing therapy. This was only possible in the 117 children over
the age of 2 years at the start of continuing therapy as
younger children had cranial irradiation delayed until after
their second birthday and received intrathecal Mtx at month-
ly intervals till then and on these occasions systemic Mtx was
omitted.
Median Mtx pharmacokinetic measurements, Mtx and 6-
MP doses and ANC were used regardless of the number of
determinations made. The pattern of change of drug dosage
and ANC over the eight courses was considered in the subset
of (>2 years old) patients who completed therapy (94
patients) using analysis of variance).
Preliminary univariate analysis was carried out to assess
the influence of each variable using the Cox proportional
hazard model to give an estimate of the regression coefficient
and its corresponding confidence interval. The assumption of
proportionality of hazards was tested by fitting a time depen-
dent covariate for the coefficient in the form (z - z*) (t - t*)
where z and t are covariates, * denotes their respective means
and when the coefficient was found to be significant, the
hazard rate was expressed as a function of time and the
covariate. A positive coefficient indicated that higher values
of the explanatory variable were associated with an increase
in the risk of relapse, and a negative coefficient indicated
high values associated with a decrease in the risk of relapse.
A non-zero time coefficient would imply an increasing
(coefficient >0) or decreasing (coefficient <0) hazard with
time. The effect of covariates on the risk of relapse was
assessed for the three time periods; during therapy (the first 2
years), after completion of treatment (more than 2 years after
diagnosis) and the entire period.
Multivariate analysis using a Cox proportional hazard
model with forward stepwise selection was carried out to
select the subset of variables most related to EFS. At each
step, no variable with a P value greater than 0.02 (0.01 in
children under the age of 2 years) was entered and the
variable with the smallest P was entered. The analysis was
repeated on the subset of >2 years old to include drug
dosage and ANC.
For presentation of results, covariates were dichotomised
at the median value. The survival functions were compared
using the Breslow Log-Rank test. The number of patients
used in each analysis is shown in Table I.
Data management and description was carried out using
SAS statistical software and statistical analysis using BMDP
statistical software. Graphical output was using Ghost-80
graphics library.
Permission for the study was granted by the Joint Commit-
tee of Ethical Practice of the Hospital for Sick Children and
the Institute of Child Health.
Results
Pharmacokinetics ofMtx absorption
The median Mtx concentration on 127 patients studied was
0.225 JM (range 0.03-0.56AM) and the median AUC was
4.3 AM h-' (range 0.35-9.36 JM h-l) (Table IT). For those
patients randomised to receive IM Mtx the median clearance
was 6.77 1 h-2 (range 4.26-12.53). Those patients who receiv-
ed Mtx via an IM route had a significantly higher median
concentration (P<0.001) and AUC24 (P<0.001).
Dosage ofMtx and 6-MP and ANC
One hundred and seventeen children who were over the age
of 2 at the commencement of continuing therapy were pre-
scribed a median of 94% of the protocol dose of Mtx with a
range of 30-107%. Children who received IM Mtx received
significantly lower doses than those receiving the drug by the
Table I Numbers ofpatients used in each analysis
Number ofpatients
(number ofevents)
Variable On treatment Offtherapy Totalperiod
Univariate analyses
Sex
(68 boys, 59 girls)
Route
(64 oral, 63 IM) ) 127 (20) 105 (33) 127 (53)
Initial WBC
Age )
Median Mtx conc
Median AUC 120 (18) 101 (30) 120 (48)
Mtx clearance (IM only) 57 (7) 50 (18) 57 (25)
Median prescribed dose
-Mtx )
- 6-MP ) 117 (19) 97 (31) 117 (50)
)
Median neutrophil count
Multivariate analyses (excluding Mtx clearance; IM only)
Covariates and 120 (18) 101 (30) 120 (48)
Mtx absorption data
All variables, patients 111 (17) 94 (29) 111 (46)
>2 years at diagnosis
TableII ComparisonofMtxpharmacokineticmeasurementsand Mtx
and 6-MPdosage inchildrenwho received oral or IM Mtx(medianand
ranges are shown)
Wilcoxon signed
Oral Mtx IM Mtx rank significance
Median Mtx concentration 0.183 0.27 P<0.001
JAM (0.04-0.41) (0.03-0.56)
Median Mtx AUC 3.19 5.75 P<0.001
lMh-' (0.35-6.55) (3.42-9.36)
Clearance 6.77
(4.26-12.53)
Median Mtx 96 90 P<0.001
% ofprescribed dose (74-107) (30-104)
Median 6-MP 102 108.5 P= 0.76
% ofprescribed dose (68.5-143) (31-155.5)
Median ANC x 1091' 2.5 2.66 P= 0.75
(1.4-4.3) (1.1-4.85)
oral route (P = 0.001). During the 2 years oftherapy the Mtx
dose administered during each of the eight courses fell signi-
ficantly (P = 0.002) but the reduction was similar for both
oral and IM groups (P = 0.9).
The overall median dose of 6-MP administered also varied
with a median 103.5% (range 31-155.5%). There was no
difference in the percentage dose of 6-MP administered
between children receiving IM or oral Mtx (P = 0.94). In
contrast to Mtx there was a significant trend for patients to
receive increasingly more 6-MP during therapy (P = 0.001).
Again this was the same for both groups (P = 0.53). There
was no relationship between the dose of methotrexate and
6-mercaptopurine.
The dose of vincristine and prednisone was constant in all
patients. The median ANC was 2.55 x I0'1- (range of
1.10-4.85) with no difference between those patients receiv-
ing oral or IM Mtx (P = 0.97) and there was no trend during
therapy (P = 0.9). As expected the median ANC was signi-
ficantly correlated with the median percentage 6-MP dose
(P = 0.001) and to a much lesser extent with the median Mtx
dose.
Neither age, sex nor presenting white cell count were cor-
related with the percentage administered dose of 6-MP and
Mtx or with the absolute neutrophil count.
Factors affecting EFS
Seventy-four patients are still in remission. There were 29
bone marrow, seven central nervous system, nine testicular
and three other relapses. Five patients had concomitant cen-
tral nervous system and bone marrow relapse. Two patients
died in remission from infection.METHOTREXATE LEVELS AND SURVIVAL IN ALL 171
The effect of presenting white cell count, age, sex, route of
administration, Mtx clearance, median Mtx concentration,
AUC24 for Mtx, Mtx dose, 6-MP dose and median ANC on
EFS in an univariate analysis is shown in Table III. The only
significant prognostic variable affecting relapse on and off
therapy was white blood cell count at presentation
(P<0.001). The route of Mtx administration and Mtx phar-
macokinetic values had no effect on the rate of leukaemic
relapse (Figures I and 2).
Patients with a higher white cell count and older children
had an increased rate of relapse on therapy (P<0.001,
P= 0.01).
After completion of therapy the risk of leukaemic relapse
was greater in those children who had received lower than
the median Mtx dose (P = 0.001) (Figure 3) or higher 6-MP
dose (P = 0.03) (Figure 4). The effect of these variables on
leukaemic relapse became less important with increasing
time. Age and white cell count were not factors affecting
relapse after completion of therapy.
The results of the multivariate analyses are shown in Table
IV. The addition of other covariates to the model after white
cell count did not significantly produce a better model for
relapses on therapy. However, with relapses after completion
of therapy the percentage median Mtx dose had some impor-
tance on survival.
As sample sizes of patients with isolated bone marrow,
testicular and central nervous system relapse were small, it
was not possible to obtain statistically significant results
when examining these subgroups. Therefore only the EFS
could be related to their considered variables. Any sub-
division of patients into prognostic subcategories by white
cell count and age also was not possible because of the small
numbers of relapses in each subgroup.
Discussion
Previous studies have shown that there is great interindivi-
dual variation in the pharmacokinetics of Mtx when given by
mouth or intramuscularly to children with ALL (Freeman
Narrod, 1962; Kearney et al., 1979; Craft et al., 1980; Pinker-
ton et al., 1980; Balis et al., 1983; Pearson et al., 1987). There
has been speculation that differences in Mtx handling could
account for some of the otherwise unexplained relapses
which occur in children with ALL and an early study report-
ed that patients with a higher I h level after an oral dose had
a better chance of survival (Craft et al., 1980). The present
study was designed to test whether there was an association
between Mtx pharmacokinetic parameters and EFS. We have
already reported that in this study IM Mtx was associated
with higher peak concentrations and AUC but that inter-
and intrapatient variability was no less than when given
orally (Pearson et al., 1987). On examining the EFS in terms
of Mtx pharmacokinetics it has been shown that higher peak
concentrations and AUC are not associated with improved
survival either when oral and IM are combined or separately.
This is in contrast to the findings from two previous studies
from St Jude's Children's Hospital (Evans et al., 1984; Evans
et al., 1986) where slower Mtx clearances and higher steady
state serum concentrations were initially associated with an
improved EFS rate. However, with further follow up this
survival advantage was lost (Evans, 1989). In these studies
the dose of Mtx administered was greater than in the present
study. The degree of Mtx polyglutamate formation has been
shown to vary with different doses and exposure times to
Mtx (Chabner et al., 1985) and this may explain the differ-
ences in these findings.
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Figure 1 Event free survival in 127 patients who had Mtx
absorption studies performed. The children were grouped accord-
ing to the rate of Mtx administration (P= 0.05).
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Figure 2 Event free survival in 120 patients who had Mtx
absorption studies performed. The children are grouped accord-
ing to their median Mtx AUC24 (P = 0.9).
Table III Univariate regression analysis of prognostic variables affecting outcome
On After completion Total
therapy oftherapy period
Coefficient P Coefficient P Coefficient P
Children 0- 14 years
Sex 0.17 0.7 -0.36 0.31 -0.21 0.58
WBC at presentation 0.007 <0.001 0.15 0.11 0.009 <0.001
Age at presentation 0.16 0.01 -0.015 0.8 0.09 0.17
Route of Mtx administration -0.4 0.38 0.65 0.16 0.25 0.5
Median Mtx concentration B, 1.03 0.08 -2.9 0.19 - 1.31 0.44
B2 -0.86
Median Mtx (AUC24) 0.03 0.83 0.003 0.95 0.04 0.9
Median Mtx clearance -0.08 0.75 0.15 0.56 0.06 0.7
Children > 2 years
Median % prescribed -0.014 0.44 B, -0.004 0.001 0.019 0.1
Mtx administered B2 -0.003
Median % prescribed -0.01 0.18 B, 0.030 0.03 0.01 0.94
6-MP administered B2 0.004
Median absolute -0.1 0.14 0.014 0.32 0.17 0.6
neutrophil count
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Figure 3 Event free survival in 117 patients who were over the
age of two at the commencement of maintenance therapy and
had the % of the Mtx dose which they received calculated.
Children were grouped according to the percentage of the pres-
cribed Mtx dose. Significance value (P = 0.1) for all events,
(P = 0.44) for events during therapy, (P = 0.001) for events
occurring after discontinuation of therapy.
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Figure 4 Event free survival in 117 patients who had 6-
mercaptopurine dosage calculated and who were over the age of
two at the commencement of maintenance therapy. Significance
value (P = 0.94) for all events, (P = 0.18) events during the
therapy and (P = 0.03) for events occurring off therapy.
Table IV Multivariate analysis
Chi square
Period improvement P
Children 0-14 years
On therapy ( WBC 9.4 0.002
Mtx conc 5.56 0.02
[time dependent]
After completion of therapy WBC 5.9 0.03
Total period WBC 11.1 0.001
Children >2 years
On therapy WBC 7.33 0.007
After completion of therapy ( Mtx dose 7.0 0.008
[time dependent]
WBC 6.5 0.01
Total period WBC 9.9 0.005
WBC -white blood count at diagnosis. Mtx conc - Median methotrex-
ate concentration. Mtx dose - median % administered Methotrexate
dose.
The lack of any association between EFS and median Mtx
levels is in conflict with a previous Medical Research Council
(MRC) study (Craft et al., 1980) where there was a signi-
ficant correlation between 1 h levels and outcome. The MRC
study was one of the earliest in this field and suffered from
various problems. The method of Mtx administration was
not standardised, it was a multicentre study and the results
were reported at an early stage. With time these significant
findings have not persisted (Craft A.W. - personal observa-
tion). The present study was carried out in a single institu-
tion, with standardised method of Mtx administration and all
patients have been followed for at least 7 years. Therefore the
present findings are considerably more robust.
Despite each child having only three Mtx absorption
studies and intraindividual variability in Mtx absorption
(Pearson et al., 1987) differences in prognosis should have
been sufficient to be detected ifmonitoring Mtx levels are to
be of practical prognostic importance in childhood ALL.
Although with 6-MP administration 2 weeks out of three,
this is not the ideal model to consider drug dosage and ANC,
this study has given an opportunity to examine associations
between the dose of both Mtx and 6-MP which had been
prescribed and relapse. In addition, whether those patients
who had 'maximally tolerated therapy' as judged by the
ANC had a more favourable outcome can be investigated.
The design of the study was such that Mtx dose would be
constant and the 6-MP dose would be altered to the maxi-
mum which would result in an ANC> 1.0 x 1091-. In spite
of this being a single institution study the dose of Mtx given
varied from 45.6 to 106.9% It is unclear why children given
IM Mtx received a lower dose than those receiving the drug
by the oral route, especially as administration of a fixed Mtx
dose was one of the principal guidelines of the protocol. The
formulation of IM Mtx was such that some approximation
of the dose was necessary. It is possible that there was an
unrecognised subconscious trend to round down the metho-
trexate dosage as there was less physician familiarity with IM
Mtx and concern that it would produce increased toxicity.
The trend for a gradual reduction in Mtx, but not 6-MP,
dose during therapy presumably occurred because the dose
was not increased to compensate for the child's growth.
The dose of 6-MP was the same in children receiving oral
and IM Mtx. The reason for the increase in 6-MP dose
throughout therapy is also unknown. Whilst this study was
in progress the MRC UKALL VIII trial was opened. In the
MRC trial clinicians were encouraged to administer the max-
imally tolerated dose of Mtx and 6-MP. This philosophy may
have had an effect on the prescribing pattern of physicians
treating patients on the PLOD protocol. However, there was
no significant change in the ANC throughout therapy which
would have been expected if this had been a major effect.
After completion of therapy those patients given higher
doses of Mtx (although no patient received more than 107%
of the Mtx dose) had a higher EFS. However, patients who
could only tolerate low doses of 6-MP because of neutro-
paenia had a better EFS suggesting that when the maximally
tolerated treatment is given a more favourable outcome may
result. These findings could indicate that it is important
to administer both Mtx and 6-MP dosage at the maxi-
mally tolerated dosage which is compatible with an
ANC<l.0 x1091-'.
The median ANC throughout therapy (2.55 x 109 -1) was
quite high, suggesting that some children could have received
higher doses of Mtx and 6-MP. It is perhaps for this reason
that no relationship between ANC and EFS was observed
and 6-MP and Mtx dose were the only variables related to
EFS. If therapy had been more 'intense' a relationship
between ANC and EFS may have been apparent.
Similar findings, relating 6-MP dosage to survival, have
previously been made from a retrospective study (Silberman
et al., 1985). Those patients who received a lower dose of
6-MP due to greater toxicity had a greater EFS. The better
survival in the MRC UKALL VIII trial compared to pre-
vious studies has been attributed to the sustained use of
maximally tolerated dose of 6-MP and Mtx (Medical
Research Council, 1986). In other cancers halfdoses ofdrugs
have been similarly shown to be associated with increased
relapse rate (Bonadona & Valagussa, 1981; Hiyniuk & Bush,
1984; Carde et al., 1983).
Recent evidence suggests that intracellular metabolism of
6-MP and Mtx may affect myelotoxicity and leukaemia
relapse. Red blood cell intracellular 6-thioguanine nucleotides
have been related to ANC 2 weeks later (Lennard et al.,
1983). Also children who have higher red blood cell 6-
thioguanine nucleotide concentrations have a higher EFS
(Lennard et al., 1990). Higher intracellular Mtx and Mtx
polyglutamates, in 'good prognosis' children with ALL has
also been associated with a better outcome (Whitehead et al.,
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1990). Thus patients who tolerate low doses of 6-MP and
Mtx may be those who have higher intracellular concentra-
tions of metabolites.
This study does not address the important variables of
patient and physician compliance in drug administration
(Smith et al., 1979). It did not compare differences between
prescribed and received doses of orally administered cyto-
toxic drugs. Failure in compliance may be a factor account-
ing for some relapses in childhood ALL, however specifically
designed studies are needed to investigate this problem.
The overall randomised study of oral vs IM Mtx during
continuing therapy of childhood ALL showed that IM Mtx
produced no advantage in EFS and was associated with a
greater incidence of neutrotoxicity, infectious complications
and patients discomfort (Chessells et al., 1987). Also IM Mtx
did not appear to benefit any subgroup of patients. IM Mtx
does produce higher peak concentrations and AUC, however
there is no less variability than with oral Mtx. Although the
unknown variable of patient compliance in drug administra-
tion is overcome with the administration by this route, both
the higher serum concentrations and certainty of administra-
tion were not associated with improved leukaemia relapse
free survival in this trial.
The mere achievement of higher serum concentrations of
Mtx in the treatment of childhood ALL is not sufficient to
improve the rate of cure in this disease. The relationship of
Mtx and 6-MP dosage with EFS may indicate that those
children who receive higher drug doses at levels as near as
possible to those which are maximally tolerable have the
greatest chance of cure of their disease.
Jeanette Stevens for data collection; the Leukaemia Research Fund
for support of DRL; the North of England Children's Cancer
Research Fund for support of ADJP and HA.
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